Invention Grant
US08119126B2 Inhibiting vascularization using antibodies to CXCR4 and SDF-1
有权
使用CXCR4和SDF-1的抗体抑制血管形成
- Patent Title: Inhibiting vascularization using antibodies to CXCR4 and SDF-1
- Patent Title (中): 使用CXCR4和SDF-1的抗体抑制血管形成
-
Application No.: US10785230Application Date: 2004-02-25
-
Publication No.: US08119126B2Publication Date: 2012-02-21
- Inventor: Tadamitsu Kishimoto , Takashi Nagasawa , Kazunobu Tachibana
- Applicant: Tadamitsu Kishimoto , Takashi Nagasawa , Kazunobu Tachibana
- Applicant Address: JP Tokyo JP Osaka
- Assignee: Chugai Seiyaku Kabushiki Kasha,Tadamitsu Kishimoto
- Current Assignee: Chugai Seiyaku Kabushiki Kasha,Tadamitsu Kishimoto
- Current Assignee Address: JP Tokyo JP Osaka
- Agency: Morgan, Lewis & Bockius LLP
- Priority: JPP10-095448 19980324
- Main IPC: A61K39/00
- IPC: A61K39/00 ; A61K39/395

Abstract:
This invention provides a therapeutic agent for inhibiting neovascularization, a therapeutic agent for a solid cancer, a therapeutic agent for a disease pathologically caused by neovascularization, and a therapeutic agent for repairing a tissue comprising as the effective ingredient, a substance that potentiates the action of CXCR4.Based on the finding that vascularization is suppressed in CXCR4 knockout mice, it becomes possible to prepare a therapeutic agent for suppressing vascularization, a therapeutic agent for a solid cancer, a therapeutic agent for a disease pathologically caused by neovascularization, each of which comprises as the effective ingredient, a substance that inhibits the action of CXCR4, as well as to prepare a therapeutic agent for repairing a tissue comprising as the effective ingredient, a substance that potentiates the action of CXCR4. Methods for treatment are made possible that use these therapeutic agents.
Public/Granted literature
- US20040209837A1 Vascularization inhibitors Public/Granted day:2004-10-21
Information query